Global Pneumonia Testing research

Pneumonia Testing Comprehensive Study by Application (Hospitals, Diagnostic Laboratories, Homecare, Others), Technology (Enzyme Linked Immunosorbent Assay, Immunofluorescence, Western Blot, Polymerase Chain Reaction, Immunohistochemistry, Others), Distribution Channels (Direct Sales, Indirect Sales {Online Retailers, Specialty Stores, Pharmacy}), Method (Immunodiagnostics, Molecular Diagnostics, Point of Care (POC) Testing), Testing (Non-laboratory Tests {Radiography, Computed Tomography, Bronchoscopy, Others}, Laboratory Tests {CBC (Complete Blood Count), BMP (Basic Metabolic Panel), Blood Gases, Others}) Players and Region - Global Market Outlook to 2030

Pneumonia Testing Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Pneumonia Testing
Pneumonia is an infection that lowers the respiratory which is caused by bacteria, viruses, and fungi. Increasing the occurrence of pneumonia highly effect on children. According to the Centres for Disease Control and Prevention revealed that there are more than one million children and adults are affected by pneumonia in the United States regions every year. And around more than 2.5 million people have died from pneumonia across the globe. Because of this rising occurrence of pneumonia cases across the globe, the healthcare provider is highly focusing on technology advancement. For instance, such as with the help of Amazon Web Services the health care providers are using artificial intelligence in the clinical research study in the detection of pneumonia associated with plain COVID-19. In the current market situation novel coronavirus pneumonia.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketNorth America
UnitValue (USD Million)


The global Pneumonia Testing market is Strongly competitive. The major players are operating in this market are highly focusing more on R&D activities to develop new testing products for coronavirus pneumonia. Original applications are developed by market players to strengthen their geographical presence. The market major players are exploring the market by adopting various business growth strategies including mergers & acquisitions, expansions, investments, new product launches. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Pneumonia Testing market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Thermo Fisher Scientific (United States), Abbott Laboratories (United States), F-Hoffmann la Roche (Switzerland), Hologic (United States), bioMerieux (France), Becton Dickinson (United States), Bio-Rad Laboratories (United States), Meridian Biosciences (United States), Quest Diagnostics (United States) and Quidel (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are AdvanDx (United States), Beckman Coulter (United States) and Cepheid (United States).

Segmentation Overview
AMA Research has segmented the market of Global Pneumonia Testing market by , Application (Hospitals, Diagnostic Laboratories, Homecare and Others) and Region.



On the basis of geography, the market of Pneumonia Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Asia Pacific region held largest market share in the year 2023. If we see Market by Technology, the sub-segment i.e. Enzyme Linked Immunosorbent Assay will boost the Pneumonia Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channels, the sub-segment i.e. Direct Sales will boost the Pneumonia Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Method, the sub-segment i.e. Immunodiagnostics will boost the Pneumonia Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Testing, the sub-segment i.e. Non-laboratory Tests {Radiography, Computed Tomography, Bronchoscopy, Others} will boost the Pneumonia Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Advancement in Nucleic Acid Detection Tests and Along with the Development in POC Testing Products and Growing Number of Government Funding for Research & Development of Coronavirus Testing Kits

Market Growth Drivers:
Rising Occurrence of Pneumonia Across the Globe, and it is Becoming One of the Major Factors Behind the Death in Children Across the Globe

Challenges:
High Cost Associated with Pneumonia Testing

Restraints:
Lack of Testing Centres and Labs in Under Developing Countries and Huge Gap in Supply Chain in Developing Regions

Opportunities:
The increasing ratio of diagnostic tests in the developing regions including India and Africa. Furthermore, the rise in the adoption of molecular diagnostic testing in the developing economies is anticipated to deliver new revenues from the growth of the pneumonia testing market in the future.

Market Leaders and their expansionary development strategies
In May 2023, the U.S. Food and Drug Administration approved Xacduro (sulbactam for injection; durlobactam for injection), a new treatment for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii-calcoaceticus complex, for patients 18 years of age and older.
In Mar 2020, Astrotech Corporation revealed that it is developing a screening test known as BreathTest-1000, which is now under development. This test is designed to screen for volatile organic compound metabolites in human’s breath those who have infection known as COVID-19, pneumonia. Through this, the Company aims to combine the detection of COVID-19 along with pneumonia into the BreathTest-1000 instrument to deliver an immediate screening test for symptoms for COVID-19 or pneumonia.


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Pneumonia Testing Devices Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Diagnostic Laboratories
  • Homecare
  • Others
By Technology
  • Enzyme Linked Immunosorbent Assay
  • Immunofluorescence
  • Western Blot
  • Polymerase Chain Reaction
  • Immunohistochemistry
  • Others

By Distribution Channels
  • Direct Sales
  • Indirect Sales {Online Retailers, Specialty Stores, Pharmacy}

By Method
  • Immunodiagnostics
  • Molecular Diagnostics
  • Point of Care (POC) Testing

By Testing
  • Non-laboratory Tests {Radiography, Computed Tomography, Bronchoscopy, Others}
  • Laboratory Tests {CBC (Complete Blood Count), BMP (Basic Metabolic Panel), Blood Gases, Others}

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Occurrence of Pneumonia Across the Globe, and it is Becoming One of the Major Factors Behind the Death in Children Across the Globe
    • 3.3. Market Challenges
      • 3.3.1. High Cost Associated with Pneumonia Testing
    • 3.4. Market Trends
      • 3.4.1. Advancement in Nucleic Acid Detection Tests and Along with the Development in POC Testing Products
      • 3.4.2. Growing Number of Government Funding for Research & Development of Coronavirus Testing Kits
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pneumonia Testing, by Application, Technology, Distribution Channels, Method, Testing and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Pneumonia Testing (Value)
      • 5.2.1. Global Pneumonia Testing by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Diagnostic Laboratories
        • 5.2.1.3. Homecare
        • 5.2.1.4. Others
      • 5.2.2. Global Pneumonia Testing by: Technology (Value)
        • 5.2.2.1. Enzyme Linked Immunosorbent Assay
        • 5.2.2.2. Immunofluorescence
        • 5.2.2.3. Western Blot
        • 5.2.2.4. Polymerase Chain Reaction
        • 5.2.2.5. Immunohistochemistry
        • 5.2.2.6. Others
      • 5.2.3. Global Pneumonia Testing by: Distribution Channels (Value)
        • 5.2.3.1. Direct Sales
        • 5.2.3.2. Indirect Sales {Online Retailers, Specialty Stores, Pharmacy}
      • 5.2.4. Global Pneumonia Testing by: Method (Value)
        • 5.2.4.1. Immunodiagnostics
        • 5.2.4.2. Molecular Diagnostics
        • 5.2.4.3. Point of Care (POC) Testing
      • 5.2.5. Global Pneumonia Testing by: Testing (Value)
        • 5.2.5.1. Non-laboratory Tests {Radiography, Computed Tomography, Bronchoscopy, Others}
        • 5.2.5.2. Laboratory Tests {CBC (Complete Blood Count), BMP (Basic Metabolic Panel), Blood Gases, Others}
      • 5.2.6. Global Pneumonia Testing Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Pneumonia Testing (Volume)
      • 5.3.1. Global Pneumonia Testing by: Application (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Diagnostic Laboratories
        • 5.3.1.3. Homecare
        • 5.3.1.4. Others
      • 5.3.2. Global Pneumonia Testing by: Technology (Volume)
        • 5.3.2.1. Enzyme Linked Immunosorbent Assay
        • 5.3.2.2. Immunofluorescence
        • 5.3.2.3. Western Blot
        • 5.3.2.4. Polymerase Chain Reaction
        • 5.3.2.5. Immunohistochemistry
        • 5.3.2.6. Others
      • 5.3.3. Global Pneumonia Testing by: Distribution Channels (Volume)
        • 5.3.3.1. Direct Sales
        • 5.3.3.2. Indirect Sales {Online Retailers, Specialty Stores, Pharmacy}
      • 5.3.4. Global Pneumonia Testing by: Method (Volume)
        • 5.3.4.1. Immunodiagnostics
        • 5.3.4.2. Molecular Diagnostics
        • 5.3.4.3. Point of Care (POC) Testing
      • 5.3.5. Global Pneumonia Testing by: Testing (Volume)
        • 5.3.5.1. Non-laboratory Tests {Radiography, Computed Tomography, Bronchoscopy, Others}
        • 5.3.5.2. Laboratory Tests {CBC (Complete Blood Count), BMP (Basic Metabolic Panel), Blood Gases, Others}
      • 5.3.6. Global Pneumonia Testing Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Pneumonia Testing (Price)
  • 6. Pneumonia Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F-Hoffmann la Roche (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hologic (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BioMerieux (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Becton Dickinson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bio-Rad Laboratories (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Meridian Biosciences (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Quest Diagnostics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Quidel (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pneumonia Testing Sale, by Application, Technology, Distribution Channels, Method, Testing and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Pneumonia Testing (Value)
      • 7.2.1. Global Pneumonia Testing by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Diagnostic Laboratories
        • 7.2.1.3. Homecare
        • 7.2.1.4. Others
      • 7.2.2. Global Pneumonia Testing by: Technology (Value)
        • 7.2.2.1. Enzyme Linked Immunosorbent Assay
        • 7.2.2.2. Immunofluorescence
        • 7.2.2.3. Western Blot
        • 7.2.2.4. Polymerase Chain Reaction
        • 7.2.2.5. Immunohistochemistry
        • 7.2.2.6. Others
      • 7.2.3. Global Pneumonia Testing by: Distribution Channels (Value)
        • 7.2.3.1. Direct Sales
        • 7.2.3.2. Indirect Sales {Online Retailers, Specialty Stores, Pharmacy}
      • 7.2.4. Global Pneumonia Testing by: Method (Value)
        • 7.2.4.1. Immunodiagnostics
        • 7.2.4.2. Molecular Diagnostics
        • 7.2.4.3. Point of Care (POC) Testing
      • 7.2.5. Global Pneumonia Testing by: Testing (Value)
        • 7.2.5.1. Non-laboratory Tests {Radiography, Computed Tomography, Bronchoscopy, Others}
        • 7.2.5.2. Laboratory Tests {CBC (Complete Blood Count), BMP (Basic Metabolic Panel), Blood Gases, Others}
      • 7.2.6. Global Pneumonia Testing Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Pneumonia Testing (Volume)
      • 7.3.1. Global Pneumonia Testing by: Application (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Diagnostic Laboratories
        • 7.3.1.3. Homecare
        • 7.3.1.4. Others
      • 7.3.2. Global Pneumonia Testing by: Technology (Volume)
        • 7.3.2.1. Enzyme Linked Immunosorbent Assay
        • 7.3.2.2. Immunofluorescence
        • 7.3.2.3. Western Blot
        • 7.3.2.4. Polymerase Chain Reaction
        • 7.3.2.5. Immunohistochemistry
        • 7.3.2.6. Others
      • 7.3.3. Global Pneumonia Testing by: Distribution Channels (Volume)
        • 7.3.3.1. Direct Sales
        • 7.3.3.2. Indirect Sales {Online Retailers, Specialty Stores, Pharmacy}
      • 7.3.4. Global Pneumonia Testing by: Method (Volume)
        • 7.3.4.1. Immunodiagnostics
        • 7.3.4.2. Molecular Diagnostics
        • 7.3.4.3. Point of Care (POC) Testing
      • 7.3.5. Global Pneumonia Testing by: Testing (Volume)
        • 7.3.5.1. Non-laboratory Tests {Radiography, Computed Tomography, Bronchoscopy, Others}
        • 7.3.5.2. Laboratory Tests {CBC (Complete Blood Count), BMP (Basic Metabolic Panel), Blood Gases, Others}
      • 7.3.6. Global Pneumonia Testing Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Pneumonia Testing (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pneumonia Testing: by Application(USD Million)
  • Table 2. Pneumonia Testing Hospitals , by Region USD Million (2018-2023)
  • Table 3. Pneumonia Testing Diagnostic Laboratories , by Region USD Million (2018-2023)
  • Table 4. Pneumonia Testing Homecare , by Region USD Million (2018-2023)
  • Table 5. Pneumonia Testing Others , by Region USD Million (2018-2023)
  • Table 6. Pneumonia Testing: by Technology(USD Million)
  • Table 7. Pneumonia Testing Enzyme Linked Immunosorbent Assay , by Region USD Million (2018-2023)
  • Table 8. Pneumonia Testing Immunofluorescence , by Region USD Million (2018-2023)
  • Table 9. Pneumonia Testing Western Blot , by Region USD Million (2018-2023)
  • Table 10. Pneumonia Testing Polymerase Chain Reaction , by Region USD Million (2018-2023)
  • Table 11. Pneumonia Testing Immunohistochemistry , by Region USD Million (2018-2023)
  • Table 12. Pneumonia Testing Others , by Region USD Million (2018-2023)
  • Table 13. Pneumonia Testing: by Distribution Channels(USD Million)
  • Table 14. Pneumonia Testing Direct Sales , by Region USD Million (2018-2023)
  • Table 15. Pneumonia Testing Indirect Sales {Online Retailers, Specialty Stores, Pharmacy} , by Region USD Million (2018-2023)
  • Table 16. Pneumonia Testing: by Method(USD Million)
  • Table 17. Pneumonia Testing Immunodiagnostics , by Region USD Million (2018-2023)
  • Table 18. Pneumonia Testing Molecular Diagnostics , by Region USD Million (2018-2023)
  • Table 19. Pneumonia Testing Point of Care (POC) Testing , by Region USD Million (2018-2023)
  • Table 20. Pneumonia Testing: by Testing(USD Million)
  • Table 21. Pneumonia Testing Non-laboratory Tests {Radiography, Computed Tomography, Bronchoscopy, Others} , by Region USD Million (2018-2023)
  • Table 22. Pneumonia Testing Laboratory Tests {CBC (Complete Blood Count), BMP (Basic Metabolic Panel), Blood Gases, Others} , by Region USD Million (2018-2023)
  • Table 23. South America Pneumonia Testing, by Country USD Million (2018-2023)
  • Table 24. South America Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 25. South America Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 26. South America Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 27. South America Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 28. South America Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 29. Brazil Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 30. Brazil Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 31. Brazil Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 32. Brazil Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 33. Brazil Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 34. Argentina Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 35. Argentina Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 36. Argentina Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 37. Argentina Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 38. Argentina Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 39. Rest of South America Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 40. Rest of South America Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 41. Rest of South America Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 42. Rest of South America Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 43. Rest of South America Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 44. Asia Pacific Pneumonia Testing, by Country USD Million (2018-2023)
  • Table 45. Asia Pacific Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 46. Asia Pacific Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 47. Asia Pacific Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 48. Asia Pacific Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 49. Asia Pacific Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 50. China Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 51. China Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 52. China Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 53. China Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 54. China Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 55. Japan Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 56. Japan Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 57. Japan Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 58. Japan Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 59. Japan Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 60. India Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 61. India Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 62. India Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 63. India Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 64. India Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 65. South Korea Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 66. South Korea Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 67. South Korea Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 68. South Korea Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 69. South Korea Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 70. Taiwan Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 71. Taiwan Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 72. Taiwan Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 73. Taiwan Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 74. Taiwan Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 75. Australia Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 76. Australia Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 77. Australia Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 78. Australia Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 79. Australia Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 81. Rest of Asia-Pacific Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 85. Europe Pneumonia Testing, by Country USD Million (2018-2023)
  • Table 86. Europe Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 87. Europe Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 88. Europe Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 89. Europe Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 90. Europe Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 91. Germany Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 92. Germany Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 93. Germany Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 94. Germany Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 95. Germany Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 96. France Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 97. France Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 98. France Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 99. France Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 100. France Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 101. Italy Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 102. Italy Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 103. Italy Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 104. Italy Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 105. Italy Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 106. United Kingdom Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 107. United Kingdom Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 108. United Kingdom Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 109. United Kingdom Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 110. United Kingdom Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 111. Netherlands Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 112. Netherlands Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 113. Netherlands Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 114. Netherlands Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 115. Netherlands Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 116. Rest of Europe Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 117. Rest of Europe Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 118. Rest of Europe Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 119. Rest of Europe Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 120. Rest of Europe Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 121. MEA Pneumonia Testing, by Country USD Million (2018-2023)
  • Table 122. MEA Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 123. MEA Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 124. MEA Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 125. MEA Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 126. MEA Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 127. Middle East Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 128. Middle East Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 129. Middle East Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 130. Middle East Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 131. Middle East Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 132. Africa Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 133. Africa Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 134. Africa Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 135. Africa Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 136. Africa Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 137. North America Pneumonia Testing, by Country USD Million (2018-2023)
  • Table 138. North America Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 139. North America Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 140. North America Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 141. North America Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 142. North America Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 143. United States Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 144. United States Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 145. United States Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 146. United States Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 147. United States Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 148. Canada Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 149. Canada Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 150. Canada Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 151. Canada Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 152. Canada Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 153. Mexico Pneumonia Testing, by Application USD Million (2018-2023)
  • Table 154. Mexico Pneumonia Testing, by Technology USD Million (2018-2023)
  • Table 155. Mexico Pneumonia Testing, by Distribution Channels USD Million (2018-2023)
  • Table 156. Mexico Pneumonia Testing, by Method USD Million (2018-2023)
  • Table 157. Mexico Pneumonia Testing, by Testing USD Million (2018-2023)
  • Table 158. Pneumonia Testing Sales: by Application(K Unit)
  • Table 159. Pneumonia Testing Sales Hospitals , by Region K Unit (2018-2023)
  • Table 160. Pneumonia Testing Sales Diagnostic Laboratories , by Region K Unit (2018-2023)
  • Table 161. Pneumonia Testing Sales Homecare , by Region K Unit (2018-2023)
  • Table 162. Pneumonia Testing Sales Others , by Region K Unit (2018-2023)
  • Table 163. Pneumonia Testing Sales: by Technology(K Unit)
  • Table 164. Pneumonia Testing Sales Enzyme Linked Immunosorbent Assay , by Region K Unit (2018-2023)
  • Table 165. Pneumonia Testing Sales Immunofluorescence , by Region K Unit (2018-2023)
  • Table 166. Pneumonia Testing Sales Western Blot , by Region K Unit (2018-2023)
  • Table 167. Pneumonia Testing Sales Polymerase Chain Reaction , by Region K Unit (2018-2023)
  • Table 168. Pneumonia Testing Sales Immunohistochemistry , by Region K Unit (2018-2023)
  • Table 169. Pneumonia Testing Sales Others , by Region K Unit (2018-2023)
  • Table 170. Pneumonia Testing Sales: by Distribution Channels(K Unit)
  • Table 171. Pneumonia Testing Sales Direct Sales , by Region K Unit (2018-2023)
  • Table 172. Pneumonia Testing Sales Indirect Sales {Online Retailers, Specialty Stores, Pharmacy} , by Region K Unit (2018-2023)
  • Table 173. Pneumonia Testing Sales: by Method(K Unit)
  • Table 174. Pneumonia Testing Sales Immunodiagnostics , by Region K Unit (2018-2023)
  • Table 175. Pneumonia Testing Sales Molecular Diagnostics , by Region K Unit (2018-2023)
  • Table 176. Pneumonia Testing Sales Point of Care (POC) Testing , by Region K Unit (2018-2023)
  • Table 177. Pneumonia Testing Sales: by Testing(K Unit)
  • Table 178. Pneumonia Testing Sales Non-laboratory Tests {Radiography, Computed Tomography, Bronchoscopy, Others} , by Region K Unit (2018-2023)
  • Table 179. Pneumonia Testing Sales Laboratory Tests {CBC (Complete Blood Count), BMP (Basic Metabolic Panel), Blood Gases, Others} , by Region K Unit (2018-2023)
  • Table 180. South America Pneumonia Testing Sales, by Country K Unit (2018-2023)
  • Table 181. South America Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 182. South America Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 183. South America Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 184. South America Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 185. South America Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 186. Brazil Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 187. Brazil Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 188. Brazil Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 189. Brazil Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 190. Brazil Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 191. Argentina Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 192. Argentina Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 193. Argentina Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 194. Argentina Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 195. Argentina Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 196. Rest of South America Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 197. Rest of South America Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 198. Rest of South America Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 199. Rest of South America Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 200. Rest of South America Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 201. Asia Pacific Pneumonia Testing Sales, by Country K Unit (2018-2023)
  • Table 202. Asia Pacific Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 203. Asia Pacific Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 204. Asia Pacific Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 205. Asia Pacific Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 206. Asia Pacific Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 207. China Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 208. China Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 209. China Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 210. China Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 211. China Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 212. Japan Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 213. Japan Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 214. Japan Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 215. Japan Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 216. Japan Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 217. India Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 218. India Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 219. India Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 220. India Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 221. India Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 222. South Korea Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 223. South Korea Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 224. South Korea Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 225. South Korea Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 226. South Korea Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 227. Taiwan Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 228. Taiwan Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 229. Taiwan Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 230. Taiwan Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 231. Taiwan Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 232. Australia Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 233. Australia Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 234. Australia Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 235. Australia Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 236. Australia Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 237. Rest of Asia-Pacific Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 238. Rest of Asia-Pacific Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 239. Rest of Asia-Pacific Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 240. Rest of Asia-Pacific Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 241. Rest of Asia-Pacific Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 242. Europe Pneumonia Testing Sales, by Country K Unit (2018-2023)
  • Table 243. Europe Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 244. Europe Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 245. Europe Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 246. Europe Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 247. Europe Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 248. Germany Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 249. Germany Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 250. Germany Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 251. Germany Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 252. Germany Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 253. France Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 254. France Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 255. France Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 256. France Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 257. France Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 258. Italy Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 259. Italy Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 260. Italy Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 261. Italy Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 262. Italy Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 263. United Kingdom Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 264. United Kingdom Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 265. United Kingdom Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 266. United Kingdom Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 267. United Kingdom Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 268. Netherlands Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 269. Netherlands Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 270. Netherlands Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 271. Netherlands Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 272. Netherlands Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 273. Rest of Europe Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 274. Rest of Europe Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 275. Rest of Europe Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 276. Rest of Europe Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 277. Rest of Europe Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 278. MEA Pneumonia Testing Sales, by Country K Unit (2018-2023)
  • Table 279. MEA Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 280. MEA Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 281. MEA Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 282. MEA Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 283. MEA Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 284. Middle East Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 285. Middle East Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 286. Middle East Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 287. Middle East Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 288. Middle East Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 289. Africa Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 290. Africa Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 291. Africa Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 292. Africa Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 293. Africa Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 294. North America Pneumonia Testing Sales, by Country K Unit (2018-2023)
  • Table 295. North America Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 296. North America Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 297. North America Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 298. North America Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 299. North America Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 300. United States Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 301. United States Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 302. United States Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 303. United States Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 304. United States Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 305. Canada Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 306. Canada Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 307. Canada Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 308. Canada Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 309. Canada Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 310. Mexico Pneumonia Testing Sales, by Application K Unit (2018-2023)
  • Table 311. Mexico Pneumonia Testing Sales, by Technology K Unit (2018-2023)
  • Table 312. Mexico Pneumonia Testing Sales, by Distribution Channels K Unit (2018-2023)
  • Table 313. Mexico Pneumonia Testing Sales, by Method K Unit (2018-2023)
  • Table 314. Mexico Pneumonia Testing Sales, by Testing K Unit (2018-2023)
  • Table 315. Company Basic Information, Sales Area and Its Competitors
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Pneumonia Testing: by Application(USD Million)
  • Table 326. Pneumonia Testing Hospitals , by Region USD Million (2025-2030)
  • Table 327. Pneumonia Testing Diagnostic Laboratories , by Region USD Million (2025-2030)
  • Table 328. Pneumonia Testing Homecare , by Region USD Million (2025-2030)
  • Table 329. Pneumonia Testing Others , by Region USD Million (2025-2030)
  • Table 330. Pneumonia Testing: by Technology(USD Million)
  • Table 331. Pneumonia Testing Enzyme Linked Immunosorbent Assay , by Region USD Million (2025-2030)
  • Table 332. Pneumonia Testing Immunofluorescence , by Region USD Million (2025-2030)
  • Table 333. Pneumonia Testing Western Blot , by Region USD Million (2025-2030)
  • Table 334. Pneumonia Testing Polymerase Chain Reaction , by Region USD Million (2025-2030)
  • Table 335. Pneumonia Testing Immunohistochemistry , by Region USD Million (2025-2030)
  • Table 336. Pneumonia Testing Others , by Region USD Million (2025-2030)
  • Table 337. Pneumonia Testing: by Distribution Channels(USD Million)
  • Table 338. Pneumonia Testing Direct Sales , by Region USD Million (2025-2030)
  • Table 339. Pneumonia Testing Indirect Sales {Online Retailers, Specialty Stores, Pharmacy} , by Region USD Million (2025-2030)
  • Table 340. Pneumonia Testing: by Method(USD Million)
  • Table 341. Pneumonia Testing Immunodiagnostics , by Region USD Million (2025-2030)
  • Table 342. Pneumonia Testing Molecular Diagnostics , by Region USD Million (2025-2030)
  • Table 343. Pneumonia Testing Point of Care (POC) Testing , by Region USD Million (2025-2030)
  • Table 344. Pneumonia Testing: by Testing(USD Million)
  • Table 345. Pneumonia Testing Non-laboratory Tests {Radiography, Computed Tomography, Bronchoscopy, Others} , by Region USD Million (2025-2030)
  • Table 346. Pneumonia Testing Laboratory Tests {CBC (Complete Blood Count), BMP (Basic Metabolic Panel), Blood Gases, Others} , by Region USD Million (2025-2030)
  • Table 347. South America Pneumonia Testing, by Country USD Million (2025-2030)
  • Table 348. South America Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 349. South America Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 350. South America Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 351. South America Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 352. South America Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 353. Brazil Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 354. Brazil Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 355. Brazil Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 356. Brazil Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 357. Brazil Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 358. Argentina Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 359. Argentina Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 360. Argentina Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 361. Argentina Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 362. Argentina Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 363. Rest of South America Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 364. Rest of South America Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 365. Rest of South America Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 366. Rest of South America Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 367. Rest of South America Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 368. Asia Pacific Pneumonia Testing, by Country USD Million (2025-2030)
  • Table 369. Asia Pacific Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 370. Asia Pacific Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 371. Asia Pacific Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 372. Asia Pacific Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 373. Asia Pacific Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 374. China Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 375. China Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 376. China Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 377. China Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 378. China Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 379. Japan Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 380. Japan Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 381. Japan Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 382. Japan Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 383. Japan Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 384. India Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 385. India Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 386. India Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 387. India Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 388. India Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 389. South Korea Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 390. South Korea Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 391. South Korea Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 392. South Korea Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 393. South Korea Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 394. Taiwan Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 395. Taiwan Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 396. Taiwan Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 397. Taiwan Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 398. Taiwan Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 399. Australia Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 400. Australia Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 401. Australia Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 402. Australia Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 403. Australia Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 404. Rest of Asia-Pacific Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 405. Rest of Asia-Pacific Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 406. Rest of Asia-Pacific Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 407. Rest of Asia-Pacific Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 408. Rest of Asia-Pacific Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 409. Europe Pneumonia Testing, by Country USD Million (2025-2030)
  • Table 410. Europe Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 411. Europe Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 412. Europe Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 413. Europe Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 414. Europe Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 415. Germany Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 416. Germany Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 417. Germany Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 418. Germany Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 419. Germany Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 420. France Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 421. France Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 422. France Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 423. France Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 424. France Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 425. Italy Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 426. Italy Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 427. Italy Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 428. Italy Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 429. Italy Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 430. United Kingdom Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 431. United Kingdom Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 432. United Kingdom Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 433. United Kingdom Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 434. United Kingdom Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 435. Netherlands Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 436. Netherlands Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 437. Netherlands Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 438. Netherlands Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 439. Netherlands Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 440. Rest of Europe Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 441. Rest of Europe Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 442. Rest of Europe Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 443. Rest of Europe Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 444. Rest of Europe Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 445. MEA Pneumonia Testing, by Country USD Million (2025-2030)
  • Table 446. MEA Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 447. MEA Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 448. MEA Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 449. MEA Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 450. MEA Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 451. Middle East Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 452. Middle East Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 453. Middle East Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 454. Middle East Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 455. Middle East Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 456. Africa Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 457. Africa Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 458. Africa Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 459. Africa Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 460. Africa Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 461. North America Pneumonia Testing, by Country USD Million (2025-2030)
  • Table 462. North America Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 463. North America Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 464. North America Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 465. North America Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 466. North America Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 467. United States Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 468. United States Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 469. United States Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 470. United States Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 471. United States Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 472. Canada Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 473. Canada Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 474. Canada Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 475. Canada Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 476. Canada Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 477. Mexico Pneumonia Testing, by Application USD Million (2025-2030)
  • Table 478. Mexico Pneumonia Testing, by Technology USD Million (2025-2030)
  • Table 479. Mexico Pneumonia Testing, by Distribution Channels USD Million (2025-2030)
  • Table 480. Mexico Pneumonia Testing, by Method USD Million (2025-2030)
  • Table 481. Mexico Pneumonia Testing, by Testing USD Million (2025-2030)
  • Table 482. Pneumonia Testing Sales: by Application(K Unit)
  • Table 483. Pneumonia Testing Sales Hospitals , by Region K Unit (2025-2030)
  • Table 484. Pneumonia Testing Sales Diagnostic Laboratories , by Region K Unit (2025-2030)
  • Table 485. Pneumonia Testing Sales Homecare , by Region K Unit (2025-2030)
  • Table 486. Pneumonia Testing Sales Others , by Region K Unit (2025-2030)
  • Table 487. Pneumonia Testing Sales: by Technology(K Unit)
  • Table 488. Pneumonia Testing Sales Enzyme Linked Immunosorbent Assay , by Region K Unit (2025-2030)
  • Table 489. Pneumonia Testing Sales Immunofluorescence , by Region K Unit (2025-2030)
  • Table 490. Pneumonia Testing Sales Western Blot , by Region K Unit (2025-2030)
  • Table 491. Pneumonia Testing Sales Polymerase Chain Reaction , by Region K Unit (2025-2030)
  • Table 492. Pneumonia Testing Sales Immunohistochemistry , by Region K Unit (2025-2030)
  • Table 493. Pneumonia Testing Sales Others , by Region K Unit (2025-2030)
  • Table 494. Pneumonia Testing Sales: by Distribution Channels(K Unit)
  • Table 495. Pneumonia Testing Sales Direct Sales , by Region K Unit (2025-2030)
  • Table 496. Pneumonia Testing Sales Indirect Sales {Online Retailers, Specialty Stores, Pharmacy} , by Region K Unit (2025-2030)
  • Table 497. Pneumonia Testing Sales: by Method(K Unit)
  • Table 498. Pneumonia Testing Sales Immunodiagnostics , by Region K Unit (2025-2030)
  • Table 499. Pneumonia Testing Sales Molecular Diagnostics , by Region K Unit (2025-2030)
  • Table 500. Pneumonia Testing Sales Point of Care (POC) Testing , by Region K Unit (2025-2030)
  • Table 501. Pneumonia Testing Sales: by Testing(K Unit)
  • Table 502. Pneumonia Testing Sales Non-laboratory Tests {Radiography, Computed Tomography, Bronchoscopy, Others} , by Region K Unit (2025-2030)
  • Table 503. Pneumonia Testing Sales Laboratory Tests {CBC (Complete Blood Count), BMP (Basic Metabolic Panel), Blood Gases, Others} , by Region K Unit (2025-2030)
  • Table 504. South America Pneumonia Testing Sales, by Country K Unit (2025-2030)
  • Table 505. South America Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 506. South America Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 507. South America Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 508. South America Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 509. South America Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 510. Brazil Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 511. Brazil Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 512. Brazil Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 513. Brazil Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 514. Brazil Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 515. Argentina Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 516. Argentina Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 517. Argentina Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 518. Argentina Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 519. Argentina Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 520. Rest of South America Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 521. Rest of South America Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 522. Rest of South America Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 523. Rest of South America Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 524. Rest of South America Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 525. Asia Pacific Pneumonia Testing Sales, by Country K Unit (2025-2030)
  • Table 526. Asia Pacific Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 527. Asia Pacific Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 528. Asia Pacific Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 529. Asia Pacific Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 530. Asia Pacific Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 531. China Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 532. China Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 533. China Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 534. China Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 535. China Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 536. Japan Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 537. Japan Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 538. Japan Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 539. Japan Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 540. Japan Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 541. India Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 542. India Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 543. India Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 544. India Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 545. India Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 546. South Korea Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 547. South Korea Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 548. South Korea Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 549. South Korea Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 550. South Korea Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 551. Taiwan Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 552. Taiwan Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 553. Taiwan Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 554. Taiwan Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 555. Taiwan Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 556. Australia Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 557. Australia Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 558. Australia Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 559. Australia Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 560. Australia Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 561. Rest of Asia-Pacific Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 562. Rest of Asia-Pacific Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 563. Rest of Asia-Pacific Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 564. Rest of Asia-Pacific Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 565. Rest of Asia-Pacific Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 566. Europe Pneumonia Testing Sales, by Country K Unit (2025-2030)
  • Table 567. Europe Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 568. Europe Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 569. Europe Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 570. Europe Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 571. Europe Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 572. Germany Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 573. Germany Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 574. Germany Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 575. Germany Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 576. Germany Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 577. France Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 578. France Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 579. France Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 580. France Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 581. France Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 582. Italy Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 583. Italy Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 584. Italy Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 585. Italy Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 586. Italy Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 587. United Kingdom Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 588. United Kingdom Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 589. United Kingdom Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 590. United Kingdom Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 591. United Kingdom Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 592. Netherlands Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 593. Netherlands Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 594. Netherlands Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 595. Netherlands Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 596. Netherlands Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 597. Rest of Europe Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 598. Rest of Europe Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 599. Rest of Europe Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 600. Rest of Europe Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 601. Rest of Europe Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 602. MEA Pneumonia Testing Sales, by Country K Unit (2025-2030)
  • Table 603. MEA Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 604. MEA Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 605. MEA Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 606. MEA Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 607. MEA Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 608. Middle East Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 609. Middle East Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 610. Middle East Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 611. Middle East Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 612. Middle East Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 613. Africa Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 614. Africa Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 615. Africa Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 616. Africa Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 617. Africa Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 618. North America Pneumonia Testing Sales, by Country K Unit (2025-2030)
  • Table 619. North America Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 620. North America Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 621. North America Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 622. North America Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 623. North America Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 624. United States Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 625. United States Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 626. United States Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 627. United States Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 628. United States Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 629. Canada Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 630. Canada Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 631. Canada Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 632. Canada Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 633. Canada Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 634. Mexico Pneumonia Testing Sales, by Application K Unit (2025-2030)
  • Table 635. Mexico Pneumonia Testing Sales, by Technology K Unit (2025-2030)
  • Table 636. Mexico Pneumonia Testing Sales, by Distribution Channels K Unit (2025-2030)
  • Table 637. Mexico Pneumonia Testing Sales, by Method K Unit (2025-2030)
  • Table 638. Mexico Pneumonia Testing Sales, by Testing K Unit (2025-2030)
  • Table 639. Research Programs/Design for This Report
  • Table 640. Key Data Information from Secondary Sources
  • Table 641. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pneumonia Testing: by Application USD Million (2018-2023)
  • Figure 5. Global Pneumonia Testing: by Technology USD Million (2018-2023)
  • Figure 6. Global Pneumonia Testing: by Distribution Channels USD Million (2018-2023)
  • Figure 7. Global Pneumonia Testing: by Method USD Million (2018-2023)
  • Figure 8. Global Pneumonia Testing: by Testing USD Million (2018-2023)
  • Figure 9. South America Pneumonia Testing Share (%), by Country
  • Figure 10. Asia Pacific Pneumonia Testing Share (%), by Country
  • Figure 11. Europe Pneumonia Testing Share (%), by Country
  • Figure 12. MEA Pneumonia Testing Share (%), by Country
  • Figure 13. North America Pneumonia Testing Share (%), by Country
  • Figure 14. Global Pneumonia Testing: by Application K Unit (2018-2023)
  • Figure 15. Global Pneumonia Testing: by Technology K Unit (2018-2023)
  • Figure 16. Global Pneumonia Testing: by Distribution Channels K Unit (2018-2023)
  • Figure 17. Global Pneumonia Testing: by Method K Unit (2018-2023)
  • Figure 18. Global Pneumonia Testing: by Testing K Unit (2018-2023)
  • Figure 19. South America Pneumonia Testing Share (%), by Country
  • Figure 20. Asia Pacific Pneumonia Testing Share (%), by Country
  • Figure 21. Europe Pneumonia Testing Share (%), by Country
  • Figure 22. MEA Pneumonia Testing Share (%), by Country
  • Figure 23. North America Pneumonia Testing Share (%), by Country
  • Figure 24. Global Pneumonia Testing share by Players 2023 (%)
  • Figure 25. Global Pneumonia Testing share by Players (Top 3) 2023(%)
  • Figure 26. Global Pneumonia Testing share by Players (Top 5) 2023(%)
  • Figure 27. BCG Matrix for key Companies
  • Figure 28. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 29. Thermo Fisher Scientific (United States) Revenue: by Geography 2023
  • Figure 30. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 31. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 32. F-Hoffmann la Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. F-Hoffmann la Roche (Switzerland) Revenue: by Geography 2023
  • Figure 34. Hologic (United States) Revenue, Net Income and Gross profit
  • Figure 35. Hologic (United States) Revenue: by Geography 2023
  • Figure 36. BioMerieux (France) Revenue, Net Income and Gross profit
  • Figure 37. BioMerieux (France) Revenue: by Geography 2023
  • Figure 38. Becton Dickinson (United States) Revenue, Net Income and Gross profit
  • Figure 39. Becton Dickinson (United States) Revenue: by Geography 2023
  • Figure 40. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 41. Bio-Rad Laboratories (United States) Revenue: by Geography 2023
  • Figure 42. Meridian Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 43. Meridian Biosciences (United States) Revenue: by Geography 2023
  • Figure 44. Quest Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 45. Quest Diagnostics (United States) Revenue: by Geography 2023
  • Figure 46. Quidel (United States) Revenue, Net Income and Gross profit
  • Figure 47. Quidel (United States) Revenue: by Geography 2023
  • Figure 48. Global Pneumonia Testing: by Application USD Million (2025-2030)
  • Figure 49. Global Pneumonia Testing: by Technology USD Million (2025-2030)
  • Figure 50. Global Pneumonia Testing: by Distribution Channels USD Million (2025-2030)
  • Figure 51. Global Pneumonia Testing: by Method USD Million (2025-2030)
  • Figure 52. Global Pneumonia Testing: by Testing USD Million (2025-2030)
  • Figure 53. South America Pneumonia Testing Share (%), by Country
  • Figure 54. Asia Pacific Pneumonia Testing Share (%), by Country
  • Figure 55. Europe Pneumonia Testing Share (%), by Country
  • Figure 56. MEA Pneumonia Testing Share (%), by Country
  • Figure 57. North America Pneumonia Testing Share (%), by Country
  • Figure 58. Global Pneumonia Testing: by Application K Unit (2025-2030)
  • Figure 59. Global Pneumonia Testing: by Technology K Unit (2025-2030)
  • Figure 60. Global Pneumonia Testing: by Distribution Channels K Unit (2025-2030)
  • Figure 61. Global Pneumonia Testing: by Method K Unit (2025-2030)
  • Figure 62. Global Pneumonia Testing: by Testing K Unit (2025-2030)
  • Figure 63. South America Pneumonia Testing Share (%), by Country
  • Figure 64. Asia Pacific Pneumonia Testing Share (%), by Country
  • Figure 65. Europe Pneumonia Testing Share (%), by Country
  • Figure 66. MEA Pneumonia Testing Share (%), by Country
  • Figure 67. North America Pneumonia Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific (United States)
  • Abbott Laboratories (United States)
  • F-Hoffmann la Roche (Switzerland)
  • Hologic (United States)
  • bioMerieux (France)
  • Becton Dickinson (United States)
  • Bio-Rad Laboratories (United States)
  • Meridian Biosciences (United States)
  • Quest Diagnostics (United States)
  • Quidel (United States)
Additional players considered in the study are as follows:
AdvanDx (United States) , Beckman Coulter (United States) , Cepheid (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 159 Pages 85 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pneumonia Testing research Quantitative research analysis
Global Pneumonia Testing research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Thermo Fisher Scientific (United States), Abbott Laboratories (United States), F-Hoffmann la Roche (Switzerland), Hologic (United States), bioMerieux (France), Becton Dickinson (United States), Bio-Rad Laboratories (United States), Meridian Biosciences (United States), Quest Diagnostics (United States) and Quidel (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancement in Nucleic Acid Detection Tests and Along with the Development in POC Testing Products " is seen as one of major influencing trends for Pneumonia Testing Market during projected period 2023-2030.
The Pneumonia Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Pneumonia Testing research Report?

Have a Query? Click Here

Other Related Reports

Animal Healthcare Comprehensive Study by Type (Vaccines, Anti-Bacterial / Antibiotic, Anti-Chronic Respiratory Disease, Anticoccidials, Antihelmintics, Disinfectant, Enzymes, Fly Binder / Control, Gu...
$ 3750
Latex Allergy Comprehensive Study by Type (IgE-mediated allergic reaction (Type I), Allergic contact dermatitis (Type IV), Irritant contact dermatitis), Application (Healthcare workers, Rubber indust...
$ 3750
Maternal Health Comprehensive Study by Type (Hormones, Nutritive, Analgesics, Anti-Infectives, Others), Application (General Health, Bone & Joint Health, Gastrointestinal Health, Immunity, Energy & W...
$ 3650
Metabolic Cart Comprehensive Study by Type (The Breath-By-Breath System, The Mixing Chamber System), Application (Hospital, Private Clinic, Nursing Home, Others), Product (Desktop Device Type, Ground...
$ 3500
Biologics Drug Development Comprehensive Study by Type (Clinical Manufacturing, Formulation Development, Bioassay Development, Analytical Services), Application (In-House, Outsource, Pharma Excess) P...
$ 3500
Apron Racks Comprehensive Study by Type (Wall-Mounted, Mobile), Application (Hospitals, Clinics, Industry, Research Labs, Others), Distribution Channel (OEM, Company Supplier, Retailer, Others) Playe...
$ 3500